Alnylam to Present Phase I RSV Data at PAS Meeting
Alnylam Pharmaceuticals said this week that it will present data from its phase I trials of its respiratory syncytial virus drug ALN-RSV01 at the 2006 Pediatric Academic Societies' annual meeting being held in San Francisco.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.